nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A1—polycystic ovary syndrome	0.524	1	CbGaD
Thalidomide—PTGS2—ovarian follicle—polycystic ovary syndrome	0.00857	0.0682	CbGeAlD
Thalidomide—Anaemia megaloblastic—Metformin—polycystic ovary syndrome	0.00819	0.095	CcSEcCtD
Thalidomide—CYP2C19—urine—polycystic ovary syndrome	0.0053	0.0422	CbGeAlD
Thalidomide—TNF—vagina—polycystic ovary syndrome	0.00488	0.0389	CbGeAlD
Thalidomide—CYP1A2—urine—polycystic ovary syndrome	0.00433	0.0345	CbGeAlD
Thalidomide—CRBN—embryo—polycystic ovary syndrome	0.00425	0.0339	CbGeAlD
Thalidomide—CYP2C9—urine—polycystic ovary syndrome	0.00411	0.0327	CbGeAlD
Thalidomide—CYP2E1—urine—polycystic ovary syndrome	0.00389	0.031	CbGeAlD
Thalidomide—FGFR2—embryo—polycystic ovary syndrome	0.00381	0.0304	CbGeAlD
Thalidomide—NFKB1—endometrium—polycystic ovary syndrome	0.00371	0.0296	CbGeAlD
Thalidomide—CRBN—adrenal cortex—polycystic ovary syndrome	0.00349	0.0278	CbGeAlD
Thalidomide—NFKB1—uterus—polycystic ovary syndrome	0.00342	0.0273	CbGeAlD
Thalidomide—NFKB1—pituitary gland—polycystic ovary syndrome	0.00336	0.0268	CbGeAlD
Thalidomide—NFKB1—adipose tissue—polycystic ovary syndrome	0.00335	0.0267	CbGeAlD
Thalidomide—Toothache—Metformin—polycystic ovary syndrome	0.00317	0.0368	CcSEcCtD
Thalidomide—CRBN—endometrium—polycystic ovary syndrome	0.00311	0.0248	CbGeAlD
Thalidomide—NFKB1—adrenal gland—polycystic ovary syndrome	0.003	0.0239	CbGeAlD
Thalidomide—Nail disorder—Metformin—polycystic ovary syndrome	0.00298	0.0345	CcSEcCtD
Thalidomide—CRBN—uterus—polycystic ovary syndrome	0.00287	0.0228	CbGeAlD
Thalidomide—CRBN—pituitary gland—polycystic ovary syndrome	0.00282	0.0224	CbGeAlD
Thalidomide—CRBN—adipose tissue—polycystic ovary syndrome	0.00281	0.0223	CbGeAlD
Thalidomide—NFKB1—female gonad—polycystic ovary syndrome	0.0028	0.0223	CbGeAlD
Thalidomide—NFKB1—vagina—polycystic ovary syndrome	0.00278	0.0222	CbGeAlD
Thalidomide—NFKB1—endocrine gland—polycystic ovary syndrome	0.0026	0.0207	CbGeAlD
Thalidomide—FGFR2—uterus—polycystic ovary syndrome	0.00257	0.0205	CbGeAlD
Thalidomide—CRBN—adrenal gland—polycystic ovary syndrome	0.00252	0.02	CbGeAlD
Thalidomide—FGFR2—adipose tissue—polycystic ovary syndrome	0.00251	0.02	CbGeAlD
Thalidomide—CRBN—female gonad—polycystic ovary syndrome	0.00235	0.0187	CbGeAlD
Thalidomide—CRBN—vagina—polycystic ovary syndrome	0.00233	0.0186	CbGeAlD
Thalidomide—Blood disorder—Metformin—polycystic ovary syndrome	0.00231	0.0268	CcSEcCtD
Thalidomide—FGFR2—adrenal gland—polycystic ovary syndrome	0.00225	0.018	CbGeAlD
Thalidomide—CRBN—endocrine gland—polycystic ovary syndrome	0.00218	0.0174	CbGeAlD
Thalidomide—Accidental injury—Metformin—polycystic ovary syndrome	0.00218	0.0253	CcSEcCtD
Thalidomide—FGFR2—female gonad—polycystic ovary syndrome	0.0021	0.0167	CbGeAlD
Thalidomide—Menadione—MTHFR—polycystic ovary syndrome	0.00197	0.625	CrCbGaD
Thalidomide—FGFR2—endocrine gland—polycystic ovary syndrome	0.00196	0.0156	CbGeAlD
Thalidomide—Neuropathy—Metformin—polycystic ovary syndrome	0.00181	0.021	CcSEcCtD
Thalidomide—Lightheadedness—Metformin—polycystic ovary syndrome	0.00173	0.02	CcSEcCtD
Thalidomide—Injury—Metformin—polycystic ovary syndrome	0.00152	0.0177	CcSEcCtD
Thalidomide—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00144	0.0167	CcSEcCtD
Thalidomide—Lethargy—Metformin—polycystic ovary syndrome	0.00143	0.0166	CcSEcCtD
Thalidomide—Pain in extremity—Metformin—polycystic ovary syndrome	0.0014	0.0163	CcSEcCtD
Thalidomide—Migraine—Metformin—polycystic ovary syndrome	0.00138	0.016	CcSEcCtD
Thalidomide—Dehydration—Metformin—polycystic ovary syndrome	0.0013	0.0151	CcSEcCtD
Thalidomide—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00129	0.015	CcSEcCtD
Thalidomide—Breast disorder—Metformin—polycystic ovary syndrome	0.00127	0.0147	CcSEcCtD
Thalidomide—Cramp muscle—Metformin—polycystic ovary syndrome	0.00126	0.0146	CcSEcCtD
Thalidomide—Abdominal distension—Metformin—polycystic ovary syndrome	0.00122	0.0141	CcSEcCtD
Thalidomide—Influenza—Metformin—polycystic ovary syndrome	0.00121	0.014	CcSEcCtD
Thalidomide—Pancreatitis—Metformin—polycystic ovary syndrome	0.00119	0.0138	CcSEcCtD
Thalidomide—Menadione—CYP1A1—polycystic ovary syndrome	0.00118	0.375	CrCbGaD
Thalidomide—Angina pectoris—Metformin—polycystic ovary syndrome	0.00118	0.0137	CcSEcCtD
Thalidomide—PTGS2—embryo—polycystic ovary syndrome	0.00116	0.00923	CbGeAlD
Thalidomide—Neutropenia—Metformin—polycystic ovary syndrome	0.00113	0.0131	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00113	0.0131	CcSEcCtD
Thalidomide—Drowsiness—Metformin—polycystic ovary syndrome	0.00108	0.0125	CcSEcCtD
Thalidomide—Infestation—Metformin—polycystic ovary syndrome	0.00108	0.0125	CcSEcCtD
Thalidomide—Infestation NOS—Metformin—polycystic ovary syndrome	0.00108	0.0125	CcSEcCtD
Thalidomide—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00106	0.0123	CcSEcCtD
Thalidomide—Bradycardia—Metformin—polycystic ovary syndrome	0.000987	0.0114	CcSEcCtD
Thalidomide—Rhinitis—Metformin—polycystic ovary syndrome	0.000972	0.0113	CcSEcCtD
Thalidomide—Hepatitis—Metformin—polycystic ovary syndrome	0.000969	0.0112	CcSEcCtD
Thalidomide—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000964	0.0112	CcSEcCtD
Thalidomide—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000955	0.0111	CcSEcCtD
Thalidomide—PTGS2—adrenal cortex—polycystic ovary syndrome	0.000949	0.00756	CbGeAlD
Thalidomide—CYP2C19—vagina—polycystic ovary syndrome	0.000939	0.00748	CbGeAlD
Thalidomide—CYP1A1—uterus—polycystic ovary syndrome	0.00093	0.00741	CbGeAlD
Thalidomide—CYP1A1—adipose tissue—polycystic ovary syndrome	0.00091	0.00725	CbGeAlD
Thalidomide—Eye disorder—Metformin—polycystic ovary syndrome	0.000906	0.0105	CcSEcCtD
Thalidomide—Cardiac disorder—Metformin—polycystic ovary syndrome	0.0009	0.0104	CcSEcCtD
Thalidomide—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000889	0.00708	CbGeAlD
Thalidomide—PTGS1—endometrium—polycystic ovary syndrome	0.000887	0.00706	CbGeAlD
Thalidomide—Angiopathy—Metformin—polycystic ovary syndrome	0.000879	0.0102	CcSEcCtD
Thalidomide—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000878	0.00699	CbGeAlD
Thalidomide—Immune system disorder—Metformin—polycystic ovary syndrome	0.000876	0.0102	CcSEcCtD
Thalidomide—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000874	0.0101	CcSEcCtD
Thalidomide—Chills—Metformin—polycystic ovary syndrome	0.00087	0.0101	CcSEcCtD
Thalidomide—PTGS2—endometrium—polycystic ovary syndrome	0.000848	0.00675	CbGeAlD
Thalidomide—Malnutrition—Metformin—polycystic ovary syndrome	0.000844	0.00979	CcSEcCtD
Thalidomide—Flatulence—Metformin—polycystic ovary syndrome	0.000831	0.00964	CcSEcCtD
Thalidomide—Dysgeusia—Metformin—polycystic ovary syndrome	0.000826	0.00958	CcSEcCtD
Thalidomide—PTGS1—uterus—polycystic ovary syndrome	0.000817	0.00651	CbGeAlD
Thalidomide—Muscle spasms—Metformin—polycystic ovary syndrome	0.000811	0.00941	CcSEcCtD
Thalidomide—PTGS1—pituitary gland—polycystic ovary syndrome	0.000802	0.00639	CbGeAlD
Thalidomide—PTGS1—adipose tissue—polycystic ovary syndrome	0.000799	0.00637	CbGeAlD
Thalidomide—Vision blurred—Metformin—polycystic ovary syndrome	0.000795	0.00922	CcSEcCtD
Thalidomide—Tremor—Metformin—polycystic ovary syndrome	0.000791	0.00917	CcSEcCtD
Thalidomide—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000783	0.00908	CcSEcCtD
Thalidomide—PTGS2—uterus—polycystic ovary syndrome	0.000781	0.00622	CbGeAlD
Thalidomide—PTGS2—pituitary gland—polycystic ovary syndrome	0.000767	0.00611	CbGeAlD
Thalidomide—PTGS2—adipose tissue—polycystic ovary syndrome	0.000764	0.00608	CbGeAlD
Thalidomide—Malaise—Metformin—polycystic ovary syndrome	0.000761	0.00883	CcSEcCtD
Thalidomide—CYP1A1—female gonad—polycystic ovary syndrome	0.000761	0.00606	CbGeAlD
Thalidomide—Syncope—Metformin—polycystic ovary syndrome	0.000757	0.00878	CcSEcCtD
Thalidomide—CYP1A1—vagina—polycystic ovary syndrome	0.000756	0.00602	CbGeAlD
Thalidomide—Palpitations—Metformin—polycystic ovary syndrome	0.000746	0.00865	CcSEcCtD
Thalidomide—CYP2E1—adrenal gland—polycystic ovary syndrome	0.000744	0.00593	CbGeAlD
Thalidomide—CYP3A5—female gonad—polycystic ovary syndrome	0.000744	0.00593	CbGeAlD
Thalidomide—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000742	0.0086	CcSEcCtD
Thalidomide—CYP3A5—vagina—polycystic ovary syndrome	0.000739	0.00589	CbGeAlD
Thalidomide—Hypertension—Metformin—polycystic ovary syndrome	0.000729	0.00845	CcSEcCtD
Thalidomide—Myalgia—Metformin—polycystic ovary syndrome	0.000718	0.00833	CcSEcCtD
Thalidomide—Chest pain—Metformin—polycystic ovary syndrome	0.000718	0.00833	CcSEcCtD
Thalidomide—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000717	0.00571	CbGeAlD
Thalidomide—PTGS1—adrenal gland—polycystic ovary syndrome	0.000717	0.00571	CbGeAlD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000713	0.00828	CcSEcCtD
Thalidomide—Discomfort—Metformin—polycystic ovary syndrome	0.00071	0.00823	CcSEcCtD
Thalidomide—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000708	0.00564	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000692	0.00551	CbGeAlD
Thalidomide—Oedema—Metformin—polycystic ovary syndrome	0.000689	0.00799	CcSEcCtD
Thalidomide—PTGS2—adrenal gland—polycystic ovary syndrome	0.000685	0.00546	CbGeAlD
Thalidomide—Infection—Metformin—polycystic ovary syndrome	0.000684	0.00794	CcSEcCtD
Thalidomide—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000681	0.00542	CbGeAlD
Thalidomide—Shock—Metformin—polycystic ovary syndrome	0.000678	0.00786	CcSEcCtD
Thalidomide—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000675	0.00783	CcSEcCtD
Thalidomide—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000674	0.00782	CcSEcCtD
Thalidomide—Skin disorder—Metformin—polycystic ovary syndrome	0.000669	0.00776	CcSEcCtD
Thalidomide—PTGS1—female gonad—polycystic ovary syndrome	0.000668	0.00532	CbGeAlD
Thalidomide—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000666	0.00772	CcSEcCtD
Thalidomide—PTGS1—vagina—polycystic ovary syndrome	0.000664	0.00529	CbGeAlD
Thalidomide—Anorexia—Metformin—polycystic ovary syndrome	0.000656	0.00761	CcSEcCtD
Thalidomide—CYP2E1—endocrine gland—polycystic ovary syndrome	0.000645	0.00514	CbGeAlD
Thalidomide—Hypotension—Metformin—polycystic ovary syndrome	0.000644	0.00746	CcSEcCtD
Thalidomide—PTGS2—female gonad—polycystic ovary syndrome	0.000639	0.00509	CbGeAlD
Thalidomide—PTGS2—vagina—polycystic ovary syndrome	0.000635	0.00506	CbGeAlD
Thalidomide—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000627	0.00728	CcSEcCtD
Thalidomide—PTGS1—endocrine gland—polycystic ovary syndrome	0.000622	0.00495	CbGeAlD
Thalidomide—Paraesthesia—Metformin—polycystic ovary syndrome	0.000618	0.00717	CcSEcCtD
Thalidomide—Dyspnoea—Metformin—polycystic ovary syndrome	0.000614	0.00712	CcSEcCtD
Thalidomide—Somnolence—Metformin—polycystic ovary syndrome	0.000612	0.0071	CcSEcCtD
Thalidomide—Dyspepsia—Metformin—polycystic ovary syndrome	0.000606	0.00703	CcSEcCtD
Thalidomide—Decreased appetite—Metformin—polycystic ovary syndrome	0.000599	0.00694	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000595	0.0069	CcSEcCtD
Thalidomide—PTGS2—endocrine gland—polycystic ovary syndrome	0.000594	0.00473	CbGeAlD
Thalidomide—Fatigue—Metformin—polycystic ovary syndrome	0.000594	0.00689	CcSEcCtD
Thalidomide—Constipation—Metformin—polycystic ovary syndrome	0.000589	0.00683	CcSEcCtD
Thalidomide—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000568	0.00658	CcSEcCtD
Thalidomide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000563	0.00653	CcSEcCtD
Thalidomide—Urticaria—Metformin—polycystic ovary syndrome	0.000547	0.00635	CcSEcCtD
Thalidomide—Abdominal pain—Metformin—polycystic ovary syndrome	0.000544	0.00631	CcSEcCtD
Thalidomide—Asthenia—Metformin—polycystic ovary syndrome	0.000494	0.00573	CcSEcCtD
Thalidomide—Pruritus—Metformin—polycystic ovary syndrome	0.000487	0.00565	CcSEcCtD
Thalidomide—Diarrhoea—Metformin—polycystic ovary syndrome	0.000471	0.00547	CcSEcCtD
Thalidomide—Dizziness—Metformin—polycystic ovary syndrome	0.000455	0.00528	CcSEcCtD
Thalidomide—Vomiting—Metformin—polycystic ovary syndrome	0.000438	0.00508	CcSEcCtD
Thalidomide—Rash—Metformin—polycystic ovary syndrome	0.000434	0.00504	CcSEcCtD
Thalidomide—Dermatitis—Metformin—polycystic ovary syndrome	0.000434	0.00503	CcSEcCtD
Thalidomide—Headache—Metformin—polycystic ovary syndrome	0.000431	0.005	CcSEcCtD
Thalidomide—Nausea—Metformin—polycystic ovary syndrome	0.000409	0.00474	CcSEcCtD
Thalidomide—PTGS1—Metabolism—CYP11A1—polycystic ovary syndrome	2.17e-05	8.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRL—polycystic ovary syndrome	2.17e-05	8.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.17e-05	8.3e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.16e-05	8.26e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	2.15e-05	8.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	2.15e-05	8.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.15e-05	8.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GAB1—polycystic ovary syndrome	2.14e-05	8.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKR1C1—polycystic ovary syndrome	2.12e-05	8.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	2.11e-05	8.09e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LHB—polycystic ovary syndrome	2.1e-05	8.06e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LHB—polycystic ovary syndrome	2.1e-05	8.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	2.09e-05	8.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NAMPT—polycystic ovary syndrome	2.09e-05	7.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.07e-05	7.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.07e-05	7.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IRS1—polycystic ovary syndrome	2.06e-05	7.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.06e-05	7.88e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HSD3B2—polycystic ovary syndrome	2.06e-05	7.88e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HSD3B2—polycystic ovary syndrome	2.05e-05	7.86e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKR1C3—polycystic ovary syndrome	2.05e-05	7.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.04e-05	7.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP17A1—polycystic ovary syndrome	2.02e-05	7.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT2—polycystic ovary syndrome	2.01e-05	7.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GNAS—polycystic ovary syndrome	2.01e-05	7.7e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	2e-05	7.67e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKR1C1—polycystic ovary syndrome	1.99e-05	7.63e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKR1C1—polycystic ovary syndrome	1.99e-05	7.61e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LHB—polycystic ovary syndrome	1.98e-05	7.6e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—polycystic ovary syndrome	1.95e-05	7.46e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SULT2A1—polycystic ovary syndrome	1.95e-05	7.46e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKR1C3—polycystic ovary syndrome	1.95e-05	7.45e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HSD3B2—polycystic ovary syndrome	1.94e-05	7.43e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.91e-05	7.33e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TNRC6B—polycystic ovary syndrome	1.91e-05	7.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT2—polycystic ovary syndrome	1.91e-05	7.31e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	1.91e-05	7.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.91e-05	7.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IRS1—polycystic ovary syndrome	1.9e-05	7.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.89e-05	7.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RRM2—polycystic ovary syndrome	1.89e-05	7.22e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.88e-05	7.2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKR1C1—polycystic ovary syndrome	1.88e-05	7.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	1.87e-05	7.15e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SULT2A1—polycystic ovary syndrome	1.83e-05	7.02e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SULT2A1—polycystic ovary syndrome	1.83e-05	7.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—INS—polycystic ovary syndrome	1.82e-05	6.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—YAP1—polycystic ovary syndrome	1.82e-05	6.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.82e-05	6.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	1.8e-05	6.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.78e-05	6.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	1.78e-05	6.82e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RRM2—polycystic ovary syndrome	1.78e-05	6.8e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RRM2—polycystic ovary syndrome	1.77e-05	6.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—polycystic ovary syndrome	1.77e-05	6.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT2—polycystic ovary syndrome	1.76e-05	6.75e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.76e-05	6.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2—polycystic ovary syndrome	1.76e-05	6.73e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TH—polycystic ovary syndrome	1.75e-05	6.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NAMPT—polycystic ovary syndrome	1.75e-05	6.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.74e-05	6.65e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SULT2A1—polycystic ovary syndrome	1.73e-05	6.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP11A1—polycystic ovary syndrome	1.72e-05	6.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.71e-05	6.56e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—YAP1—polycystic ovary syndrome	1.71e-05	6.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	1.71e-05	6.55e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—YAP1—polycystic ovary syndrome	1.71e-05	6.54e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	1.7e-05	6.52e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC2A4—polycystic ovary syndrome	1.7e-05	6.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SERPINE1—polycystic ovary syndrome	1.68e-05	6.42e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RRM2—polycystic ovary syndrome	1.67e-05	6.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.67e-05	6.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2—polycystic ovary syndrome	1.67e-05	6.39e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NAMPT—polycystic ovary syndrome	1.64e-05	6.3e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NAMPT—polycystic ovary syndrome	1.64e-05	6.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TCF7L2—polycystic ovary syndrome	1.64e-05	6.28e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	1.63e-05	6.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKR1C3—polycystic ovary syndrome	1.63e-05	6.24e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP11A1—polycystic ovary syndrome	1.62e-05	6.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	1.62e-05	6.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	1.62e-05	6.22e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	1.62e-05	6.21e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	1.61e-05	6.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.61e-05	6.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC2A4—polycystic ovary syndrome	1.61e-05	6.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.61e-05	6.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.6e-05	6.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP17A1—polycystic ovary syndrome	1.6e-05	6.14e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP19A1—polycystic ovary syndrome	1.6e-05	6.12e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	1.59e-05	6.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.58e-05	6.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—polycystic ovary syndrome	1.56e-05	5.98e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	1.55e-05	5.94e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.54e-05	5.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRL—polycystic ovary syndrome	1.54e-05	5.89e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	1.54e-05	5.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKR1C3—polycystic ovary syndrome	1.53e-05	5.87e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	1.53e-05	5.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	1.53e-05	5.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.53e-05	5.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.52e-05	5.83e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.52e-05	5.82e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP17A1—polycystic ovary syndrome	1.51e-05	5.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	1.51e-05	5.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—polycystic ovary syndrome	1.49e-05	5.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—polycystic ovary syndrome	1.48e-05	5.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	1.48e-05	5.67e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	1.45e-05	5.57e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.45e-05	5.54e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	1.45e-05	5.54e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GNAS—polycystic ovary syndrome	1.43e-05	5.47e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	1.42e-05	5.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	1.41e-05	5.42e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.41e-05	5.38e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.4e-05	5.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TH—polycystic ovary syndrome	1.39e-05	5.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	1.39e-05	5.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.37e-05	5.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	1.37e-05	5.25e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NCOR1—polycystic ovary syndrome	1.36e-05	5.21e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.35e-05	5.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC2A4—polycystic ovary syndrome	1.35e-05	5.17e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—polycystic ovary syndrome	1.35e-05	5.16e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—INS—polycystic ovary syndrome	1.35e-05	5.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.33e-05	5.11e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	1.32e-05	5.06e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TH—polycystic ovary syndrome	1.31e-05	5e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TH—polycystic ovary syndrome	1.3e-05	4.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.3e-05	4.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.3e-05	4.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.3e-05	4.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	1.29e-05	4.94e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1A1—polycystic ovary syndrome	1.29e-05	4.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NCOR1—polycystic ovary syndrome	1.29e-05	4.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—polycystic ovary syndrome	1.28e-05	4.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—INS—polycystic ovary syndrome	1.28e-05	4.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC2A4—polycystic ovary syndrome	1.27e-05	4.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP19A1—polycystic ovary syndrome	1.27e-05	4.86e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	1.27e-05	4.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	1.27e-05	4.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	1.27e-05	4.85e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRG1—polycystic ovary syndrome	1.26e-05	4.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.26e-05	4.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.25e-05	4.8e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.25e-05	4.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.24e-05	4.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	1.24e-05	4.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.24e-05	4.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.24e-05	4.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.23e-05	4.73e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TH—polycystic ovary syndrome	1.23e-05	4.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.2e-05	4.61e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—polycystic ovary syndrome	1.2e-05	4.6e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	1.2e-05	4.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	1.2e-05	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP19A1—polycystic ovary syndrome	1.19e-05	4.58e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	1.19e-05	4.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.18e-05	4.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.17e-05	4.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.16e-05	4.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.16e-05	4.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.15e-05	4.4e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.14e-05	4.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—polycystic ovary syndrome	1.14e-05	4.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.13e-05	4.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNAS—polycystic ovary syndrome	1.13e-05	4.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	1.13e-05	4.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	1.1e-05	4.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS2—polycystic ovary syndrome	1.08e-05	4.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NCOR1—polycystic ovary syndrome	1.08e-05	4.13e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	1.08e-05	4.13e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	1.07e-05	4.09e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNAS—polycystic ovary syndrome	1.07e-05	4.08e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	1.06e-05	4.08e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	1.06e-05	4.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	1.03e-05	3.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A1—polycystic ovary syndrome	1.02e-05	3.92e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NCOR1—polycystic ovary syndrome	1.02e-05	3.89e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	1.01e-05	3.88e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.01e-05	3.86e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	1.01e-05	3.85e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	9.88e-06	3.79e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	9.83e-06	3.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	9.8e-06	3.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	9.76e-06	3.74e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—polycystic ovary syndrome	9.74e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	9.69e-06	3.71e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A1—polycystic ovary syndrome	9.63e-06	3.69e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	9.61e-06	3.68e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—polycystic ovary syndrome	9.61e-06	3.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	9.58e-06	3.67e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—polycystic ovary syndrome	9.55e-06	3.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—polycystic ovary syndrome	9.54e-06	3.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS1—polycystic ovary syndrome	9.46e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	9.22e-06	3.53e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	9.22e-06	3.53e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TH—polycystic ovary syndrome	9.19e-06	3.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—polycystic ovary syndrome	9.1e-06	3.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	9.07e-06	3.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—polycystic ovary syndrome	9.06e-06	3.47e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—polycystic ovary syndrome	8.98e-06	3.44e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	8.96e-06	3.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	8.94e-06	3.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT2—polycystic ovary syndrome	8.75e-06	3.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—polycystic ovary syndrome	8.63e-06	3.31e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.5e-06	3.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	8.46e-06	3.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	8.4e-06	3.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—polycystic ovary syndrome	8.32e-06	3.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	8.23e-06	3.15e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.07e-06	3.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—polycystic ovary syndrome	7.97e-06	3.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TH—polycystic ovary syndrome	7.85e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	7.84e-06	3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—polycystic ovary syndrome	7.73e-06	2.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	7.64e-06	2.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—polycystic ovary syndrome	7.63e-06	2.92e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—polycystic ovary syndrome	7.58e-06	2.91e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	7.5e-06	2.87e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	7.43e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—polycystic ovary syndrome	7.28e-06	2.79e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	7.26e-06	2.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	7.18e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—polycystic ovary syndrome	7.18e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	7.17e-06	2.74e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	7.15e-06	2.74e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—polycystic ovary syndrome	7.14e-06	2.73e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—polycystic ovary syndrome	7.13e-06	2.73e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	6.93e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	6.86e-06	2.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	6.77e-06	2.59e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	6.77e-06	2.59e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—polycystic ovary syndrome	6.73e-06	2.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	6.41e-06	2.46e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	6.32e-06	2.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	6.11e-06	2.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—polycystic ovary syndrome	5.88e-06	2.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	5.79e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	5.62e-06	2.15e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—polycystic ovary syndrome	5.58e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	5.54e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—polycystic ovary syndrome	5.51e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	5.4e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	5.12e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	5.05e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—polycystic ovary syndrome	5.02e-06	1.92e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	4.38e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	4.32e-06	1.65e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—polycystic ovary syndrome	4.29e-06	1.64e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—polycystic ovary syndrome	3.96e-06	1.52e-05	CbGpPWpGaD
